Research programme: hypercholesterolaemia therapeutics - Astrazeneca/Cholesgen
Latest Information Update: 30 Jun 2023
At a glance
- Originator AstraZeneca; Cholesgen (Shanghai)
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hypercholesterolaemia